Overview of the management of AIDS-related Kaposi's Sarcoma

Annals of Pharmacotherapy

Volumn 30, Issue 10, 1996, Pages 1150-1163

  Morris, Ashley K ^a,b   Valley, Amy Wells ^b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; BLEOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRALESIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; META ANALYSIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029760720     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001015     Document Type: Review

References (81)

1. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California. MMWR Morb Mortal Wkly Rep 1981;30:305-8.
2. Karp JE, Groopman JE, Broder S. Cancer in AIDS. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott Co., 1993:2093-110.
3. Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi's sarcoma: epidemiology, pathogenesis, histology, clinical spectrum, staging criteria, and therapy. J Am Acad Dermatol 1993;28:371-95.
4. Krown SE, Myskowski PL, Paredes J. Kaposi's sarcoma. Med Clin North Am 1992;76:235-53.
5. Northfelt DW, Kahn JO, Volberding PA. Treatment of AIDS-related Kaposi's sarcoma. Hematol Oncol Clin North Am 1991;5:297-310.
6. Beral V, Pelerman TA, Berkelman TA, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990;335:123-8.
7. Kaldor JM, Tindall B, Williamson P, Elford J, Cooper DA. Factors associated with Kaposi's sarcoma in a cohort of homosexual and bisexual men. J Acquir Immune Defic Syndr 1993;6:1145-9.
8. Rutherford GW, Schwarcz SK, Lemp GF, Barnhart JL, Rauch KJ, Warner WL, et al. The epidemiology of AIDS-related Kaposi's sarcoma in San Francisco. J Infect Dis 1989;159:569-72.
9. Cusick PS, Moss AR, Bacchetti P. Serologic variables at diagnosis with Kaposi's sarcoma (KS): predictors of shortened survival (abstract). Fifth International Conference on AIDS. Montreal, 1989.
10. Sinkovics JG. Kaposi's sarcoma: its 'oncogenes' and growth factors. Crit Rev Oncol Hematol 1991;11:87-107.
11. Ensoli B, Barillari G, Gallo RC. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. Immunol Rev 1992; 127:147-55.
12. Ensoli B, Barillari G, Gallo RC. Pathogenesis of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin North Am 1991;5:281-95.
13. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HlV infection. N Engl J Med 1995;332:1181-5.
14. Miles SA, Martinez-Maza O, Rezai A, Magpantay L, Kishimoto T, Nakamura S, et al. Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science 1992;255:1432-4.
15. Chachoua A, Krigel R, Lafleur F, Ostreicher R, Speer M, Laubenstein L, et al. Prognostic factors and staging classification of patients with epidemic Kaposi's sarcoma. J Clin Oncol 1989;7:774-80.
16. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for the uniform evaluation, response, and staging criteria. J Clin Oncol 1989;7:1201-7.
17. Levine AM. AIDS-related malignancies: the emerging epidemic. J Natl Cancer Inst 1993;85:1382-97.
18. Hill DR. The role of radiotherapy for epidemic Kaposi's sarcoma. Semin Oncol 1987;14(2 suppl 3):19-22.
19. Doyle M, Johnstone PAS, Watkins EB. Role of radiation therapy in management of pulmonary Kaposi's sarcoma. South Med J 1993;86: 285-8.
20. Epstein JB. Treatment of oral Kaposi sarcoma with intralesional vinblastine. Cancer 1993;71:1722-5.
21. Boudreaux AA, Smith LL, Cosby CD, Bason MM, Tappero JW, Berger TG. Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome. J Am Acad Dermatol 1993; 28:61-5.
22. Tappero JW, Berger TG. Caution in the use of local therapies for Kaposi's sarcoma (letter). Arch Dermatol 1993;129:42.
23. Dupuy J, Price M, Lynch G, Bruce S, Schwartz M. Intralesional interferon-alpha and zidovudine in epidemic Kaposi's sarcoma. J Am Acad Dermatol 1993;28:966-72.
24. Sulis E, Floris C, Sulis ML, Zurrida S, Piro S, Pintus A, et al. Interferon administered intralesionally in skin and oral cavity lesions in heterosexual drug addicted patients with AIDS-related Kaposi's sarcoma (letter). Eur J Cancer Clin Oncol 1989;25:759-61.
25. Kahn JO, Kaplan LD, Volberding PA, Ziegler JL, Crowe S, Saks SR, et al. Intralesional recombinant tumor necrosis factor-alpha for AIDS-associated Kaposi's sarcoma: a randomized, double-blind trial. J Acquir Immune Defic Syndr 1989;2:217-23.
26. Boente P, Sampaio C, Brandao M, Moreira ED. Local peri-lesional therapy with rhGM-CSF for Kaposi's sarcoma (letter). Lancet 1993;341: 1154.
27. Krown SE. Interferon and other biologic agents for the treatment of Kaposi's sarcoma. Hematol Oncol Clin North Am 1991;5:311-22.
28. Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey V, Walker R, et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet 1988;2:1218-22.
29. De Wit R, Schattenkerk JKME, Boucher CAB, Balcker PJM, Veenhof KHN, Danner SA. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet 1988;2:1214-7.
30. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor and lymphocyte-induced vascular responses. Cancer Res 1987; 47:5155-61.
31. Lane HC, Davey RT, Sherwin SA, Masur H, Rook AH, Manischewitz JF, et al. A Phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). J Clin Immunol 1989;9:351-61.
32. Krigel RL, Odajynk CM, Laubenstein LJ, Ostreicher R, Wernz J, Vilcek J, et al. Therapeutic trial of interferon-gamma in patients with epidemic Kaposi's sarcoma. J Biol Respir Mod 1985;4:358-64.
33. Miles SA, Wang J, Cortes E, Carden J, Marcus S, Mitsuyasu RT. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112:582-9.
34. Krigel RL, Padavic-Shaller KA, Rudolph AR, Poiesz BJ, Comis RL. Exacerbation of epidemic Kaposi's sarcoma with a combination of interleukin-2 and beta-interferon: results of a Phase II study. J Biol Respir Mod 1989;8:359-65.
35. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS. Interferon-α but not AZT suppresses HIV expression in chronically infected cell lines. Science 1989;244:575-7.
36. Real FX, Oettgen HF, Krown SE. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 1986;4:544-51.
37. Abrams DI, Volberding PA. Alpha Interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol 1987;14(2 suppl 2):43-7.
38. Groopman JE, Gottlieb MS, Goodman J, Mitsuyasu R, Conant M, Prince H, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:671-6.
39. Krown SE, Real FX, Cunningham-Rundles S, Myskowski P, Koziner B, Fein S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983;308:1071-6.
40. Fischl MA, Uttamchandani RB, Resnick L, Agarwal R, Fletcher MA, Patrone-Reese J, et al. A Phase I study of recombinant human interferon-alpha nl and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 1991;4:1-10.
41. Groopman JE, Scadden DT. Interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;110:335-7.
42. Lane HC, Falloon J, Walker RE, Deyton L, Kovacs JA, Masur H, et al. Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. Ann Intern Med 1989;111:41-50.
43. Hartshorn KV, Vogt MW, Chou TC, Blumberg RS, Byington R, Schooley RT, et al. Synergistic inhibition of human immunodeficiency viras in vitro by azidothymidine and recombinant alpha interferon. Antimicrob Agents Chemother 1987;31:168-71.
44. Krown SE, Gold JWM, Niedzwiecki D, Bundow D, Flomenberg N, Gansbacher B, et al. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112:812-21.
45. Kovacs JA, Deyton L, Davey R, Falloon J, Zunich K, Lee D, et al. Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;111:280-7.
46. Podzamczer D, Bolao F, Clotet B, Garcia P, Casanova A, Pagerols X, et al. Low-dose interferon alpha combined with zidovudine in patients with AIDS-associated Kaposi's sarcoma. J Intern Med 1993;233:247-53.
47. Scadden DT, Bering HA, Levine JD, Bresnahan J, Evans L, Epstein C, et al. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991;9:802-8.
48. Krown SE, Paredes J, Bundow D, Polsky B, Gold JWM, Flomenberg N. Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor; a Phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS. J Clin Oncol 1992;10: 1344-51.
49. Hermans P, Gori A, Lemone M, Franchioly P, Clumeck N. Possible role of granulocyte-macrophage colony stimulating factor (GM-CSF) on the rapid progression of AIDS-related Kaposi's sarcoma lesions in vivo. Br J Haematol 1994;87:413-4.
50. Shepherd FA, Evans WK, Garvey B, Read SE, Klein M, Fanning MM, et al. Combination chemotherapy and alpha-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome. Can Med Assoc J 1988;139:635-9.
51. Krigel RL, Slywotzky CM, Lonberg M, Green MD, Andes WA, Kempf R, et al. Treatment of epidemic Kaposi's sarcoma with a combination of interferon-alpha 2b and etoposide. J Biol Respir Mod 1988;7:359-64.
52. Evans LM, Itri LM, Campion M, Wyler-Plant R, Krown SE, Groopman JE, et al. Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Immunother 1991;10:39-50.
53. Volberding PA, Abrams DI, Conant M, Kaslow K, Vranizan K, Ziegler J. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:335-8.
54. Lewis B, Abrams D, Ziegler J, Conant M, Gee G, Silverberg I, et al. Single agent and combination chemotherapy of Kaposi's sarcoma in acquired immune deficiency syndrome (abstract). Proc Am Soc Clin Oncol 1983;2:59.
55. Mintzer DM, Real FX, Jovino L, Krown SE. Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immune deficiency syndrome. Ann Intern Med 1985;102:200-2.
56. Laubenstein LJ, Krigel RL, Odajynk CM, Hymes KB, Friedman-Kien A, Wernz JC, et al. Treatment of epidemic Kaposi's sarcoma with VP-16 (etoposide) or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 1984;2:1115-20.
57. Bufill JA, Grace WR, Astrow AB. Phase II trial of prolonged, low-dose, oral VP-16 in AIDS-related Kaposi' s sarcoma (KS) (abstract). Proc Am Soc Clin Oncol 1992;11:47.
58. Schwartsmann G, Sprinz E, Kronfeld M, Vinholes J, Sander E, Zampese M, et al. Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma. Eur J Cancer 1991;27:1637-9.
59. Remick SC, Reddy M, Herman D, Grace C, Harper G, Willis K, et al. Continuous infusion bleomycin in AIDS-related Kaposi's sarcoma. J Clin Oncol 1994;12:1130-6.
60. Lassoued K, Clauvel JP, Katlama C, Janier M, Picard C, Matheron S. Treatment of the acquired immune deficiency syndrome-related Kaposi's sarcoma with bleomycin as a single agent. Cancer 1990;66:1869-72.
61. Caumes E, Guermonprez G, Katlama C, Gentilini M. AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin. AIDS 1992;6: 1483-7.
62. Fischl MA, Krown SE, O'Boyle KP, Mitsuyasu R, Miles S, Wernz JC, et al. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 1993;6:259-64.
63. Gill PS, Rarick M, McCutchan JA, Slater L, Parker B, Muchmore E, et al. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991;90:427-33.
64. Gill P, Rarick M, Bernstein-Singer M, Harb M, Espina BM, Shaw V, et al. Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol 1990;13:315-9.
65. Kaplan L, Abrams D, Volberding P. Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep 1986;70:1121-2.
66. Wernz J, Laubenstein L, Hymes K, Walsh C, Muggia F. Chemotherapy and assessment of response in epidemic Kaposi's sarcoma with bleomycin/Velban (abstract). Proc Am Soc Clin Oncol 1986;5:4.
67. Gill PS, Bernstein-Singer M, Espina BM, Rarick M, Magy F, Montgomery T, et al. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma. AIDS 1992;6:1477-81.
68. Gelmann EP, Longo D, Lane HC, Fauci AS, Masur H, Wesley M, et al. Combination chemotherapy of disseminated Kaposi's sarcoma in patients with the acquired immune deficiency syndrome. Am J Med 1987; 82:456-62.
69. Shields PG, Dawkins F, Holmlund J, Cohen P, Schulof RS. Low-dose multidrug chemotherapy plus Pneumocystis carinii pneumonia prophylaxis for HIV-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 1990;3:695-700.
70. Krigel RL, Laubenstein LJ, Muggia FM. Kaposi's sarcoma: a new staging classification. Cancer Treat Rep 1983;67:6-10.
71. Hengge UR, Brockmeyer NH, Baumann M, Reimann G, Goos M. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma (letter). Lancet 1993;342:497.
72. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995; 13:914-20.
73. Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak J, et al. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 1993;341:1242-3.
74. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpele A, Esplin JA, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995;13:996-1003.
75. Gill PS, Wernz J, Scadden DT, Cohen P, von Roenn J, Chew T, et al. A randomized trial of liposomal daunorubicin (DaunoXome) versus adriamycin, bleomycin and vincristine (ABV) in 232 patients with advanced AIDS-related KS (abstract). Proc Am Soc Clin Oncol 1995;14:830.
76. Shepherd FA, Burkes RL, Paul KE, Goss PE. A Phase II study of 4′-epirubicin in the treatment of poor-risk Kaposi's sarcoma and AIDS. AIDS 1991;5:305-9.
77. Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995;346:26-8.
78. Sequus' Doxil approved for AIDS-related Kaposi's sarcoma. F-D-C Rep 1995;57(48):7-8.
79. NeXstar DaunoXome will be half the price of Sequus' Doxil. F-D-C Rep 1996;58(16):11-2.
80. Vogt MW, Durno AG, Chou TC, Coleman LA, Paradis TJ, Schooley RT, et al. Synergistic interaction of 2′,3′-dideoxycytidine (ddCyd) and recombinant interferon alpha A (rIFN-αA) on HIV replication. J Infect Dis 1988;158:378-85.
81. Myskowski PL. Kaposi's sarcoma: where do we go from here? Arch Dermatol 1993;129:1320-3.